Risk of second malignancies in patients with early-stage classical Hodgkin's lymphoma treated in a modern era

Cancer Medicine

Volumn 4, Issue 4, 2015, Pages 513-518

  Lemieux, Melissa H ^a   Solanki, Abhishek A ^a   Mahmood, Usama ^b   Chmura, Steven J ^a   Koshy, Matthew ^a,c  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF ILLINOIS HOSPITAL AND HEALTH SCIENCES SYSTEM   (United States)

Author keywords

Early stage classical Hodgkin's lymphoma; Radiotherapy; Second malignancy; SEER

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CAUSE SPECIFIC SURVIVAL; CHILD; CLASSICAL HODGKIN LYMPHOMA; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LATENT PERIOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SECOND CANCER; BREAST NEOPLASMS; HODGKIN DISEASE; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PRESCHOOL CHILD; PROSTATIC NEOPLASMS; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CHILD; CHILD, PRESCHOOL; EPIDEMIOLOGIC METHODS; FEMALE; HODGKIN DISEASE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PROSTATIC NEOPLASMS; UNITED STATES; YOUNG ADULT;

EID: 84984870459     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.405     Document Type: Article

References (21)

1. Hughes, D. B., A. R. Smith, R. Hoppe, J. B. Owen, A. Hanlon, M. Wallace, et al. 1995. Treatment planning for Hodgkin's disease: a patterns of care study. Int. J. Radiat. Oncol. Biol. Phys. 33:519-524.
2. Engert, A., P. Schiller, A. Josting, R. Herrmann, P. Koch, M. Sieber, et al. 2003. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J. Clin. Oncol. 21:3601-3608.
3. Press, O. W., M. LeBlanc, A. S. Lichter, T. M. Grogan, J. M. Unger, T. H. Wasserman, et al. 2001. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J. Clin. Oncol. 19:4238-4244.
4. Cosset, J. M., M. Henry-Amar, and J. H. Meerwaldt 1991. Long-term toxicity of early stages of Hodgkin's disease therapy: the EORTC experience. EORTC Lymphoma Cooperative Group. Ann. Oncol. 2(Suppl. 2):77-82.
5. Bonadonna, G., V. Bonfante, S. Viviani, A. Di Russo, F. Villani, and P. Valagussa 2004. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J. Clin. Oncol. 22:2835-2841.
6. Ferme, C., H. Eghbali, J. H. Meerwaldt, C. Rieux, J. Bosq, F. Berger, et al. 2007. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N. Engl. J. Med. 357:1916-1927.
7. Henry-Amar, M. 1992. Second cancer after the treatment for Hodgkin's disease: a report from the International Database on Hodgkin's Disease. Ann. Oncol. 3(Suppl. 4):117-128.
8. Biti, G., E. Cellai, S. M. Magrini, M. G. Papi, P. Ponticelli, and V. Boddi 1994. Second solid tumors and leukemia after treatment for Hodgkin's disease: an analysis of 1121 patients from a single institution. Int. J. Radiat. Oncol. Biol. Phys. 29:25-31.
9. Tukenova, M., I. Diallo, M. Hawkins, C. Guibout, E. Quiniou, H. Pacquement, et al. 2010. Long-term mortality from second malignant neoplasms in 5-year survivors of solid childhood tumors: temporal pattern of risk according to type of treatment. Cancer Epidemiol. Biomarkers Prev. 19:707-715.
10. Schoenfeld, J. D., P. M. Mauch, P. Das, B. Silver, K. J. Marcus, M. A. Stevenson, et al. 2012. Lung malignancies after Hodgkin lymphoma: disease characteristics, detection methods and clinical outcome. Ann. Oncol. 23:1813-1818.
11. Milano, M. T., H. Li, M. H. Gail, L. S. Constine, and L. B. Travis 2010. Long-term survival among patients with Hodgkin's lymphoma who developed breast cancer: a population-based study. J. Clin. Oncol. 28:5088-5096.
12. Dores, G. M., C. Metayer, R. E. Curtis, C. F. Lynch, E. A. Clarke, B. Glimelius, et al. 2002. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J. Clin. Oncol. 20:3484-3494.
13. Swerdlow, A. J., J. A. Barber, A. Horwich, D. Cunningham, S. Milan, and R. Z. Omar 1997. Second malignancy in patients with Hodgkin's disease treated at the Royal Marsden Hospital. Br. J. Cancer 75:116-123.
14. Swerdlow, A. J., A. J. Douglas, G. V. Hudson, B. V. Hudson, M. H. Bennett, and K. A. MacLennan 1992. Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation. BMJ 304:1137-1143.
15. Wendland, M. M., A. Tsodikov, M. J. Glenn, and D. K. Gaffney 2004. Time interval to the development of breast carcinoma after treatment for Hodgkin disease. Cancer 101:1275-1282.
16. Ibrahim, E. M., K. M. Abouelkhair, G. A. Kazkaz, O. A. Elmasri, and M. Al-Foheidi 2012. Risk of second breast cancer in female Hodgkin's lymphoma survivors: a meta-analysis. BMC Cancer 12:197.
17. Ibrahim, E. M., G. A. Kazkaz, K. M. Abouelkhair, M. M. Al-Mansour, T. M. Al-Fayea, M. Al-Foheidi, et al. 2013. Increased risk of second lung cancer in Hodgkin's lymphoma survivors: a meta-analysis. Lung 191:117-134.
18. Koshy, M., S. E. Rich, U. Mahmood, and Y. Kwok 2012. Declining use of radiotherapy in stage I and II Hodgkin's disease and its effect on survival and secondary malignancies. Int. J. Radiat. Oncol. Biol. Phys. 82:619-625.
19. Engert, A., J. Franklin, H. T. Eich, C. Brillant, S. Sehlen, C. Cartoni, et al. 2007. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J. Clin. Oncol. 25:3495-3502.
20. Koh, E. S., T. H. Tran, M. Heydarian, R. K. Sachs, R. W. Tsang, D. J. Brenner, et al. 2007. A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer risk. Radiat. Oncol. 2:13.
21. Franklin, J., A. Pluetschow, M. Paus, L. Specht, A. P. Anselmo, A. Aviles, et al. 2006. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann. Oncol. 17:1749-1760.